AIF1 and Alzheimer disease: Again, Iba1 immunostaining levels remained consistent across all Braak stages analysed (Fig. 4a) and reactivity was found unchanged in both diagnosed AD cases (Fig. 4d) and across disease severity (Fig. 4e).